Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Growth Outlook Shows Steady Expansion At A 8.3% CAGR Through 2030

 The Business Research Company’s 2026 market reports incorporate enhanced features, including market attractiveness scoring and analysis, total addressable market evaluation, a company scoring matrix, an interactive Excel data dashboard, refined supply chain analysis, insights on emerging startups, and overviews of key products, all aimed at improving the depth, usability, and strategic relevance of the insights delivered.

 
 What Is The Expected Market Size Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Across The Forecast Years?
 The sodium glucose cotransporter 2 (sglt2) inhibitors market size has grown strongly in recent years. It will grow from $10.96 billion in 2025 to $11.87 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising type 2 diabetes cases, unmet glycemic control needs, clinical trial success, physician awareness, regulatory approvals.
 
 The sodium glucose cotransporter 2 (sglt2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $16.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to cardio-renal benefit recognition, aging diabetic population, expanded reimbursement coverage, new drug launches, emerging market penetration. Major trends in the forecast period include expanded use beyond diabetes, increased combination therapy adoption, growth in heart failure indications, improved safety profiling, wider guideline inclusion.
 
 Download Your Free Report Sample:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
  
 Which Drivers Are Shaping The Development Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market? 
 The increasing prevalence of diabetes is expected to propel the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market going forward. Diabetes refers to a group of metabolic disorders characterized by high blood sugar levels resulting from defects in insulin secretion, insulin action, or both. The rise in diabetes cases can be attributed to factors such as urbanization, stress, environmental pollutants, and a lack of access to healthcare services. Sodium glucose cotransporter 2 (SGLT2) inhibitors are used in diabetes treatment to lower blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its excretion in urine. They also offer cardiovascular and renal benefits, making them a valuable option for managing diabetes and its complications. For instance, in March 2025, according to the Office for Health Improvement and Disparities (OHID), UK-Based English government organization, the prevalence of type 2 diabetes recorded by GPs among adults aged 17 and over in England was 7.0% in March 2024, up from 6.8% in March 2023. Therefore, the increasing prevalence of diabetes is driving the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. 
 
 Which Major Companies Are Actively Operating In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
 The sodium glucose cotransporter 2 (sglt2) inhibitors market covered in this report is segmented — 
 
 1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
 2) By Route Of Administration: Oral Route, Other Route Of Administration
 3) By End User: Hospitals, Homecare Settings, Clinics
 
 Subsegments:
 1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana 
 2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance 
 3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga 
 4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
 
 
 What Major Trends Are Impacting The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
 Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are focused on developing dual inhibitor therapeutic solutions to improve patient outcomes and manage blood sugar levels. Dual inhibitor therapeutic solutions refer to treatments that simultaneously target two different sodium-glucose cotransporters (SGLT1 and SGLT2) to enhance efficacy in managing conditions such as heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA) for sotagliflozin, a treatment for heart failure. This first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily tablet designed to reduce cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its benefits include reduced renal glucose and sodium reabsorption, which leads to preload and afterload reduction and decreased sympathetic activity.
 
 What Are The Leading Segment Divisions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
 The sodium glucose cotransporter 2 (sglt2) inhibitors market covered in this report is segmented — 
 
 1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
 2) By Route Of Administration: Oral Route, Other Route Of Administration
 3) By End User: Hospitals, Homecare Settings, Clinics
 
 Subsegments:
 1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana 
 2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance 
 3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga 
 4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
 
 
 Explore the Complete Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report:
 https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report
 
 Which Region Is Expected To Hold The Largest Share Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
  North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 #Contact Us:#
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: marketing@tbrc.info
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company